Angelini Ventures
Angelini Ventures joins $39M investment in Therini Bio to advance neurodegenerative disease treatments
Angelini Ventures has participated in a $39 million Series A extension round for Therini Bio, bringing the clinical-stage biotech company's total funding to $75 million.
Angelini Ventures joins a distinguished investor syndicate in this financing round, which includes Apollo Health Ventures, SV Health Investors' Biotech Fund, the Dementia Discovery Fund, Dolby Family Ventures, Eli Lilly and Company, Foundation for a Better World, MRL Ventures Fund, and Sanofi Ventures.
This strategic investment supports Therini's development of fibrin-targeting immunotherapies for neurodegenerative diseases driven by vascular dysfunction.
We are proud to support Therini Bio's mission to address the underlying vascular and inflammatory drivers of neurodegenerative disease through a truly novel approach. As an active CNS investor, we are excited about Therini's first-in-class selective antibody therapy targeting fibrin-mediated inflammation, offering a groundbreaking path to transform the treatment of diseases such as Alzheimer's and DME.
Thomas Thestrup,
Therini Bio's pioneering approach addresses the fundamental vascular dysfunction that contributes to neurodegenerative diseases. The company's technology specifically targets inflammatory epitopes on fibrin to halt the destructive cascade of neuroinflammation without affecting essential coagulation pathways.
The funding will enable Therini Bio to:
- Advance Phase 1b studies evaluating THN391 for Alzheimer's Disease
- Pursue clinical development for Diabetic Macular Edema applications
- Support development of a fibrin/VEGF bispecific therapy
Fabrizio Calisti, Medical Director at Angelini Ventures, will join Therini Bio as a Board Observer.
Download the full press release to learn more about this exciting partnership and Therini Bio's innovative approach to treating neurological conditions.